Euclidean Capital LLC
Follow13F filer, CIK 1825034, NEW YORK, NY
Euclidean Capital LLC reported $323,634,131 across 10 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16.
Accepted , ingested 13F-HR 0001012975-26-001061
- Period
- 2026-09-30
- Reported value
- $324M
- Holdings
- 10
- Top 10 weight
- 100%
- New
- 1
- Sold out
- 2
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| MRLNnew | +47,610 | $89.5K |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| VTVexited | -520,000 | -$113M |
| SRZNWexited | -170,833 | -$2.82K |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q3 2026
Share positions as resolved from 13F-HR 0001012975-26-001061, largest first. % of portfolio is the value over $323,634,131, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| VEUVANGUARD INTL EQUITY INDEX F | 3,243,484 | $269M | 83.15% | 0 | Timeline | ||
| INDAISHARES TR | 369,600 | $17.3M | 5.33% | 0 | Timeline | ||
| ORICORIC PHARMACEUTICALS INC | 989,410 | $13.3M | 4.12% | 0 | Timeline | ||
| TMSTEAMSHARES INC | 1,099,974 | $7.99M | 2.47% | 0 | Timeline | ||
| FHTXFOGHORN THERAPEUTICS INC | 1,573,761 | $5.62M | 1.74% | 0 | Timeline | ||
| PMVPPMV PHARMACEUTICALS INC | 2,627,643 | $4.39M | 1.36% | 0 | Timeline | ||
| SRZNSURROZEN INC | 87,696 | $2.82M | 0.87% | 0 | Timeline | ||
| ALECALECTOR INC | 1,307,858 | $2.42M | 0.75% | 0 | Timeline | ||
| TNYATENAYA THERAPEUTICS INC | 1,015,705 | $613K | 0.19% | 0 | Timeline | ||
| MRLNMERLIN INC | 47,610 | $89.5K | 0.03% | new | Timeline |
Sold out in Q3 2026
Positions in the previous quarter's report that this quarter's report no longer lists.
How Q3 2026 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001012975-26-001061 | base | 2026-11-16 |